PurMinds NeuroPharma’s Post

🎆 Happy Independence Day to our American friends and partners! Today, we celebrate freedom, innovation, and the pioneering spirit that drives progress in all fields, including biotechnology. At PurMinds NeuroPharma, we are inspired by the ingenuity and determination that have shaped the United States' contributions to science and medicine. As we work towards new neurological therapies, we embrace this spirit of innovation and collaboration. Wishing our Americian scientists, including our CSO, Dr. Alan Kozikowski, a safe and joyous celebration! #4thOfJuly #Innovation #NeuroPharma

🇨🇦 Happy Canada Day! As a proudly Canadian company, PurMinds NeuroPharma celebrates our nation's commitment to innovation and research in the field of neurological health. Today, we honor the achievements of Canadian scientists and researchers who continue to make groundbreaking contributions. Join us in celebrating our heritage and our ongoing mission to improve neurological health treatments through advanced research and development. Here's to a future filled with hope and discovery! #CanadaDay #Innovation #NeuroPharma

We're not just about novel medicines; we're poised to be a top supplier of pharmaceutical-grade psychedelic APIs and finished drug formats for clinical trials worldwide! With our Health Canada Controlled Drugs and Substances License, cGMP compliant facility, and innovative patent-pending formulation technologies, PurMinds is ready to meet the rising global demand for psilocybin, MDMA, and other pharma-grade compounds. Our vertically integrated strategy, merging proprietary therapeutics with competitive supply advantages, positions PurMinds as a powerhouse in the emerging field of psychedelic derived medicines. Find out more at purminds.com #Biotech #NeuroPharma #InvestingNews #PsychedelicMedicine #PurMinds #Innovation

At PurMinds NeuroPharma, we're pioneering the future of neurological treatment with our lead candidate, PUR501. This novel, non-hallucinogenic neuroplastogen is designed to promote neuroplasticity and is set to commence IND-enabling activities in late 2024. Discover how we're reshaping the landscape of neurological therapies. Find out more about our work at PurMinds.com #Neuroplasticity #InnovativeTherapies #PurMinds

PurMinds NeuroPharma has been featured in a new article on Medium! 🎉 Dive into the inspiring journey of our Co-Founder & CEO, Janet Qi, in "Navigating Capital As A Woman: Janet Qi Of PurMinds NeuroPharma On Top Strategies for Women Founders, CEOs, and Leaders Seeking Institutional Investments." In this insightful piece, Janet shares her top strategies for securing institutional investment, balancing leadership roles, and the unique challenges women face in the business world. From her personal experiences driving revolutionary neurological care to her leadership with the TORONTO CONCERT ORCHESTRA, Janet’s story is one of resilience, innovation, and profound impact. Highlights: Innovative Leadership: Janet’s vision for PurMinds combines her vast expertise in business development, risk assessment, and commercialization of technological innovation. Personal Motivation: Her journey began with personal tragedies, fueling her passion for breakthrough solutions in neurological care. Strategic Insights: Discover actionable strategies for women entrepreneurs seeking institutional investments. Expanding Networks: Learn about the importance of mentorship and strategic networking in securing funding. Join us in celebrating Janet's achievements and get inspired by her dedication to transforming the landscape of neuropharma and supporting women in leadership! 📖 Read the full article on Medium! Link in comments! #WomenInBusiness #Leadership #InstitutionalInvestment #Neuropharma #PurMinds #Inspiration #WomenEntrepreneurs

Exciting News! Our CEO, Janet Qi, was recently featured in a Clinical Leader article discussing the FDA advisory committee's critique of Lykos Therapeutics' MDMA studies. Despite the 9-2 vote against the validity of MDMA-assisted therapy trials, this highlights the crucial need for rigorous and well-designed clinical trials in the psychedelic field. At PurMinds, we remain committed to advancing the scientific and clinical understanding of psychedelic compounds. Our focus on meticulous research and innovative formulations, such as our proprietary psilocybin and non-hallucinogenic novel chemical entities, drives us forward. We believe in the potential of psychedelics to revolutionize neurological care and are steadfast in our pursuit of evidence-based therapies. Read the full article to learn more about our perspectives and the future of psychedelic clinical research: link in comments! #PurMinds #Psychedelics #MentalHealth #ClinicalResearch #Innovation #FDA #MDMA #PTSD

At PurMinds, we are dedicated to advancing the field of neuroscience through our focus on neuroplasticity. Neuroplasticity, the brain's ability to reorganize itself by forming new neural connections, is key to developing groundbreaking therapies for neurological and neurodegenerative disorders. Our proprietary pipelines are at the forefront of creating innovative treatments that harness the power of neuroplasticity. By promoting the brain's natural ability to heal and adapt, we aim to improve the lives of those affected by these challenging conditions. Visit purminds.com for more information on our pipeline programs. #Neuroplasticity #Neuroscience #Innovation #PurMinds #BrainHealth #Therapies #Biotech #Healthcare

We're thrilled to announce our first Controlled Substances Supply Agreement with Bluestem API Inc. to produce and supply botanical psilocybin from our Ontario-based neurolab and production facility. This agreement is a major milestone in our revenue strategy and supports Phase 1 of Bluestem's Health Canada-approved botanical psilocybin research program. The first batch of our proprietary botanical psilocybin has already been delivered! This marks the culmination of two years of dedicated research and development, positioning us as a key player in the growing market for high-quality, GMP-compliant psilocybin products. We look forward to a lasting relationship with Bluestem, contributing to crucial R&D and advancing public knowledge in the psychedelics space. #PurMinds #Psilocybin #Biotech #Neuropharma #InnovativeResearch #Psychedelics #MentalHealth #BluestemAPI 🔗 Learn more: link in comments!

Are you attending BIO 2024 in San Diego? Our CEO Janet Qi and CSO Dr. Alan Kozikowski will be meeting with potential partners and investors to discuss opportunities for collaboration and innovation. Our team is eager to share insights about our groundbreaking work in developing novel therapies for neurological and neurodegenerative disorders, especially the encouraging data on our PUR501 non-hallucinogenic neuroplastogen program. BIO International Convention 2024 is the world’s largest gathering of the biotechnology industry, bringing together public pharmaceutical companies, biotech startups, academia, non-profits, government representatives, researchers, business development professionals, and investors. It’s the perfect place to make valuable connections and build lasting relationships. Don’t miss out on the chance to connect with us at the event! #BIO2024 #SanDiego #Biotech #Pharma #Innovation #Networking #PurMinds #Partnering